WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004009087) 4-4(METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOR TREATING MUTATED-RET KINASE ASSOCIATED DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/009087    International Application No.:    PCT/IB2003/001984
Publication Date: 29.01.2004 International Filing Date: 23.05.2003
Chapter 2 Demand Filed:    02.02.2004    
IPC:
A61K 31/506 (2006.01)
Applicants: UNIVERSITY OF CINCINNATI [US/US]; Mail Location 627, Cincinnati, OH 45221-0627 (US) (For All Designated States Except US).
FAGIN, James, Alexander [US/US]; (US) (For US Only)
Inventors: FAGIN, James, Alexander; (US)
Agent: HOXIE, Thomas; c/o Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH)
Priority Data:
60/398,409 24.07.2002 US
Title (EN) 4-4(METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOR TREATING MUTATED-RET KINASE ASSOCIATED DISEASES
(FR) 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4 METHYL-3-(4-PYRIDIN-3YL)PYRIMIDIN-2-YLAMINO)PHENYL] BENZAMIDE UTILISE POUR LE TRAITEMENT DES MALADIES ASSOCIEES A UNE KINASE RET MUTEE
Abstract: front page image
(EN)The invention relates to the use of 4-(4-methylpiperazin-l-ylmethyl)-N-(4-methyl-3-(4-pyridin3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof for the treatment of mutated-RET kinase associated disease, especially mutated-RET kinase associated thyroid cancer.
(FR)L'invention concerne l'utilisation de 4-(4-méthylpipérazin-1-ylméthyl)-N-[4 méthyl-3-(4-pyridin-3yl)pyrimidin-2-ylamino)phényl] benzamide ou d'un sel pharmaceutiquement acceptable dudit composé pour le traitement d'une maladie associée à une kinase RET mutée, notamment le cancer de la thyroïde associé à une kinase RET mutée.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
Publication Language: English (EN)
Filing Language: English (EN)